A new study by True You Weight Loss and Brigham and Women's
Hospital/Harvard Medical School reveals
that patients can safely maintain their GLP-1 medications during
Endoscopic Sleeve Gastroplasty (ESG), an FDA-approved, same-day,
non-surgical procedure for adults with obesity.
CARY,
N.C., July 16, 2024 /PRNewswire-PRWeb/ -- A new
study by True You Weight Loss and Brigham and Women's
Hospital/Harvard Medical School found
that patients can safely continue their GLP-1 medications while
undergoing endoscopic sleeve gastroplasty (ESG), an FDA-approved,
same-day, non-surgical procedure for adults with obesity.
As a result of this research, our patients
can feel confident knowing that dietary modification, rather than
interrupted dosing, will allow them to safely undergo an ESG
procedure while on GLP-1 medications.
Many patients taking GLP-1 medications for weight management
and/or type 2 diabetes elect to have ESG to maximize weight loss
impact, but previous guidelines by the American Society of
Anesthesiologists recommend stopping GLP-1 medications entirely
prior to an endoscopy procedure due to safety concerns. One of the
main actions of these weight loss drugs is to slow stomach emptying
after meals, increasing feelings of satiety. Due to the slow
stomach emptying, there was concern over aspiration during surgical
procedures.
A handful of studies have evaluated modifying the timing of
GLP-1 medications in relation to endoscopic procedures. However, no
studies have examined other factors that might allow patients to
remain on their medications while still undergoing the procedures,
until now. Dr. Daniel Maselli, True
You Weight Loss Associate Director of Research and bariatric
endoscopist says he designed this research based on a comprehensive
understanding of digestion and how quickly liquids are digested
compared to solids. "Our goal was to ensure the patient's stomach
was sufficiently emptied before endoscopy rather than forcing
patients to pause their GLP-1 medication, and our study revealed
that a simple 24-hour liquid fast achieves this goal, fully
emptying the stomach and avoiding the risk of retained stomach
contents and aspiration."
GLP-1 and Endoscopic Procedures: Study Results
The study, published in May 2024
in the journal Obesity Surgery, involved a retrospective evaluation
of 57 patients undergoing ESG while on GLP-1 medications from
August 2022 to February 2024. Rather than stopping the
medication before ESG, patients followed a liquid diet the day
before and fasted for 12 hours immediately prior to their
procedure. Most of the patients were women (about 90%) and had an
average age of 44 years. About 61% had type 2 diabetes or
pre-diabetes.
The study spanned 18 months at three centers: True You Weight
Loss (Cary, NC and Atlanta, GA locations) and Brigham and Women's
Hospital (Boston, MA). All
physicians involved in this study are experts in both bariatric
endoscopy and obesity medicine, so they are uniquely suited to help
patients navigate both ESG and GLP-1 medications. The study authors
reviewed procedure notes, video footage, and anesthesia
documentation for outcomes that could be hazardous to patient
health, such as retained food in the stomach or any instances of
regurgitation or aspiration. None of these unfavorable outcomes
were observed in any of the 57 patients evaluated.
"More and more patients are using GLP-1 medications to great
weight loss success, and they've invested time, effort, and money
into these important treatments," said Dr. Maselli, noting that
missing doses can reduce the medication's effectiveness. "As a
result of this research, our patients can feel confident knowing
that dietary modification, rather than interrupted dosing, will
allow them to safely undergo an ESG procedure while on GLP-1
medications."
True You Weight Loss is the nation's first physician-founded
medical practice focused on providing non-surgical,
state-of-the-art weight loss procedures. The expert team at True
You continues to follow the dietary modification protocol evaluated
in this study with their patients seeking ESG while on GLP-1
medications.
Learn more about the innovative research studies at True You
Weight Loss.
About True You Weight Loss, PLLC
Founded by Dr. Christopher
McGowan, True You Weight Loss, PLLC, is the nation's first
dedicated endobariatric weight loss center. True You Weight Loss
offers a comprehensive range of endobariatric procedures and
support services to help patients lose weight, including endoscopic
sleeve gastroplasty (ESG), bariatric revisional procedures,
intragastric balloon placement, and medical nutrition therapy. To
learn more, visit www.trueyouweightloss.com or follow True You on
Facebook and Instagram.
About Dr. Daniel B. Maselli, MD,
ABOM
Dr. Dan Maselli is a Princeton University graduate who is
triple-board-certified in internal medicine, gastroenterology, and
obesity medicine. With more than twelve years of medical training
and expertise, Dr. Maselli is one of the country's highest volume
bariatric endoscopists. As a leader in the field, Dr. Maselli
travels around the U.S. to lead workshops and train other
physicians, and routinely delivers lectures about endobariatrics at
state and national conferences for major medical societies,
including the Georgia Gastroenterologic and Endoscopic Society and
the Obesity Medical Association.
Media Contact
Jill Dykes, True You Weight Loss,
1 919-749-8488, jill@jilldykespr.com,
https://trueyouweightloss.com/
View original content to download
multimedia:https://www.prweb.com/releases/new-research-supports-continuous-glp-1-use-during-endoscopic-procedures-302196505.html
SOURCE True You Weight Loss